<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319712440874</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319712440874</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Risk Factors</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Preoperative Assessment and Perioperative Management of Cardiovascular Risk</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Schiefermueller</surname>
<given-names>Juergen</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319712440874">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319712440874"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Myerson</surname>
<given-names>Saul</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0003319712440874">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Handa</surname>
<given-names>Ashok I.</given-names>
</name>
<degrees>FRCS</degrees>
<xref ref-type="aff" rid="aff3-0003319712440874">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319712440874"><label>1</label>SpR Cardiology, Northern Deanery, UK</aff>
<aff id="aff2-0003319712440874"><label>2</label>Department of Cardiology, John Radcliffe Hospital, University of Oxford, Oxford, UK</aff>
<aff id="aff3-0003319712440874"><label>3</label>Nuffield Department of Surgery, John Radcliffe Hospital, Headington, Oxford, UK</aff>
<author-notes>
<corresp id="corresp1-0003319712440874">Juergen Schiefermueller, SpR Cardiology, Northern Deanery, UK Email: <email>juergen@schiefermueller.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>64</volume>
<issue>2</issue>
<fpage>146</fpage>
<lpage>150</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Preoperative cardiovascular evaluation of patients scheduled to undergo surgery requires a multidisciplinary approach involving anesthetists, surgeons, and cardiologists. Within the last 5 to 10 years, there have been considerable scientific advances in this field, and the European Society of Cardiology (ESC) and the American College of Cardiology/American Heart Association(ACC/AHA) have updated their guidelines.<sup>1,11</sup> Greater emphasis now lies on preoperative clinical risk stratification and less on routine cardiac testing. Prophylactic coronary revascularization is now also seen as rarely indicated simply to lower the risk of surgery.<sup>1</sup> This review will give a brief summary of the guidelines and suggests a practical stepwise approach to evaluate the patient preoperatively.</p>
</abstract>
<kwd-group>
<kwd>preoperative assessment</kwd>
<kwd>preoperative risk</kwd>
<kwd>preoperative cardiac risk assessment</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Each year in Europe, about 7 million major surgical procedures are performed on patients with cardiac risks. This number is likely to increase by about 25% over the next 20 years due to population aging.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712440874">1</xref>
</sup> Cardiovascular complications are a major cause of perioperative morbidity and mortality, with cardiac mortality between 1% and 3%.<sup>
<xref ref-type="bibr" rid="bibr2-0003319712440874">2</xref>
<xref ref-type="bibr" rid="bibr3-0003319712440874"/>–<xref ref-type="bibr" rid="bibr6-0003319712440874">6</xref>
</sup> It is thus important to identify patients at greatest risk and institute appropriate measures to improve the outcome where feasible.</p>
<p>There are 3 major parameters to take into account when stratifying the cardiac risk in patients undergoing noncardiac surgery: (1) the clinical risk factors of the patient, (2) the patient’s functional capacity, and (3) the risks associated with the particular surgical intervention.</p>
<sec id="section1-0003319712440874">
<title>Clinical Risk Factors</title>
<p>Several risk indices have been developed over the last 3 decades, for example, by Goldman (1977), Detsky (1986) and Lee in 1999.<sup>
<xref ref-type="bibr" rid="bibr3-0003319712440874">3</xref>,<xref ref-type="bibr" rid="bibr4-0003319712440874">4</xref>,<xref ref-type="bibr" rid="bibr5-0003319712440874">5</xref>
</sup> The latter, also called revised cardiac risk index (RCRI), constitutes a modification of the original index developed by Goldman and is considered to be the best currently available validated risk prediction index in noncardiac surgery. It gives 1 point each for a history of ischemic heart disease, a history of cerebrovascular disease, heart failure, insulin-dependent diabetes mellitus, impaired renal function, and high-risk surgery. The incidence of major cardiac complications is estimated at 0.4%, 0.9%, 7%, and 11% in patients with an index of 0, 1, 2, and ≥3 points, respectively. Recently, the Lee index has been criticized for overrepresentation of thoracic, vascular, and orthopedic patients in its study population and also for only having included high-risk surgery as a factor, which might oversimplify things. A risk index developed by Boersma et al (Erasmus model),<sup>
<xref ref-type="bibr" rid="bibr8-0003319712440874">8</xref>
</sup> including more detailed information about the surgical risk and classifying operations into low, low-intermediate, intermediate-high, and high risk might improve the predictive value substantially.</p>
<table-wrap id="table1-0003319712440874" position="float">
<label>Table 1.</label>
<caption>
<p>Risk of MI and Cardiac Death Within 30 Days After Surgery<sup><xref ref-type="bibr" rid="bibr1-0003319712440874">1</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table1-0003319712440874" xlink:href="10.1177_0003319712440874-table1.tif"/>
<table>
<thead>
<tr>
<th>Low Risk &lt;1%</th>
<th>Intermediate Risk 1%-5%</th>
<th>High Risk &gt;5%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>Abdominal</td>
<td>Aortic/major vascular</td>
</tr>
<tr>
<td>Dental</td>
<td>Carotid</td>
<td>Peripheral vascular</td>
</tr>
<tr>
<td>Endocrine</td>
<td>Peripheral arterial angioplasty</td>
<td>
</td>
</tr>
<tr>
<td>Eye</td>
<td>Endovascular aneurysm repair</td>
<td>
</td>
</tr>
<tr>
<td>Gynecology</td>
<td>Head and neck</td>
<td>
</td>
</tr>
<tr>
<td>Reconstructive</td>
<td>Hip and spine</td>
<td>
</td>
</tr>
<tr>
<td>Orthopedic—minor</td>
<td>Transplant—lung/kidney/liver</td>
<td>
</td>
</tr>
<tr>
<td>Urology—minor</td>
<td>Urology—major</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319712440874">
<p>Abbreviation: MI, myocardial infarction.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0003319712440874" position="float">
<label>Table 2.</label>
<caption>
<p>Clinical Risk Factors</p>
</caption>
<graphic alternate-form-of="table2-0003319712440874" xlink:href="10.1177_0003319712440874-table2.tif"/>
<table>
<tbody>
<tr>
<td>Angina pectoris</td>
</tr>
<tr>
<td>Prior myocardial infarction</td>
</tr>
<tr>
<td>Heart failure</td>
</tr>
<tr>
<td>Stroke/transient ischemic attack</td>
</tr>
<tr>
<td>Renal dysfunction (serum creatinine &gt;170 μmol/L or a creatinine clearance of &lt;60 mL/min)</td>
</tr>
<tr>
<td>Diabetes mellitus requiring insulin therapy</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section2-0003319712440874">
<title>Functional Capacity</title>
<p>Important prognostic information can be gained from the functional capacity of the patient. This can be assessed formally with exercise testing or estimated from the ability to perform activities of daily living. It is measured in metabolic equivalents (METs), with 1 MET representing the basic metabolic rate. Climbing 2 flights of stairs requires 4 METs, and strenuous sports such as swimming or football require more than 10 METs. Patients with good functional status have a low predicted risk [even with a history of ischaemic heart disease (IHD) or other risk factors], and the patient can undergo surgery, as further investigations are rarely necessary.<sup>
<xref ref-type="bibr" rid="bibr8-0003319712440874">8</xref>
</sup> On the other hand, the inability to climb 2 flights of stairs or run a short distance (&lt;4 METs) indicates poor functional status and is associated with an increased risk of perioperative cardiovascular complications. In patients who are particularly difficult to assess, cardiopulmonary exercise testing may be helpful.</p>
</sec>
<sec id="section3-0003319712440874">
<title>Surgical Risk</title>
<p>The type of surgery and the timing of the intervention also influence the patient’s perioperative cardiovascular risk. Procedures can be classified according to the risk of nonfatal myocardial infarction (MI) and cardiac death within 30 days of surgery as low, intermediate, or high risk, with risk estimates of &lt;1%, 1% to 5%, and &gt;5%, respectively.<sup>
<xref ref-type="bibr" rid="bibr7-0003319712440874">7</xref>
</sup> Vascular surgery, especially infrainguinal revascularization procedures, poses a particularly high risk to the patient, likely because the same atherosclerotic process also causes coronary artery disease. Also of note is that laparoscopic procedures demonstrate a cardiac stress similar to an open procedure.</p>
</sec>
<sec id="section4-0003319712440874">
<title>Pathophysiology of Perioperative Cardiac Events</title>
<p>Depending on the extent and duration of the surgical intervention, neuroendocrine factors, for example, catecholamines, are released as a result of tissue injury. This leads to tachycardia and hypertension, causing increased myocardial oxygen demand and cardiac stress, in addition to the hemodynamic demands of surgery. A systemic prothrombotic state with increased platelet activity and decreased fibrinolytic activity is also seen perioperatively. Previous guidelines have focused on preoperative revascularization, but the evidence for this was poor, and 2 major trials have suggested that preoperative revascularization does not improve the perioperative event rate or long-term mortality, even in high-risk patients.<sup>
<xref ref-type="bibr" rid="bibr9-0003319712440874">9</xref>,<xref ref-type="bibr" rid="bibr10-0003319712440874">10</xref>
</sup> While this may seem surprising, the likely explanation is that the majority of perioperative MIs in stable patients occur due to stress-induced rupture of a vulnerable atherosclerotic plaque, with resulting platelet adherence and vessel thrombosis. This is often not the lesion with the tightest stenosis (which would likely be the revascularization target). Thus, the cardiac risk is mostly derived from the presence of significant coronary disease (inferring a higher risk of plaque rupture), not the most stenotic lesion itself. Noninvasive testing may be most helpful, therefore, for identifying patients with increased perioperative cardiac risk, to inform a discussion on the risks and benefits of surgery rather than to lead to a change in that risk. This may not apply in the very highest risk groups however, with severe 3-vessel coronary disease, or a significant stenosis in the proximal left anterior descending artery or left main stem, in which revascularization may provide prognostic benefit.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712440874">1</xref>
</sup>
</p>
</sec>
<sec id="section5-0003319712440874">
<title>Noninvasive Testing</title>
<p>Testing should only be performed if it changes perioperative management. In the recent European Society of Cardiology (ESC) and the American College of Cardiology/American Heart Association guidelines, stress testing is only recommended for high-risk surgery patients with more than 3 cardiovascular risk factors, while it may be “considered” for patients with &lt;3 risk factors and interventions with intermediate risk.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712440874">1</xref>,<xref ref-type="bibr" rid="bibr11-0003319712440874">11</xref>
</sup> If the patient is able to exercise, a treadmill or bicycle ergometer will provide a good estimate of the functional capacity and detect ischaemic ECG changes. Nuclear myocardial perfusion imaging (MPS) and stress echocardiography, usually using dipyridamole, adenosine, or dobutamine (DSE) as pharmacological stressors, are suitable alternatives for patients who cannot reach an ischemic threshold. Studies comparing DSE with MPS have not yet convincingly shown superiority of one technique over the other: the test of choice depends on local experience. The negative predictive values are high with all mentioned test modalities, meaning patients with normal scans have an excellent prognosis (&lt;1% risk of an event).</p>
</sec>
<sec id="section6-0003319712440874">
<title>Optimization With Medical Therapy</title>
<p>The most widely used pharmacological agent for cardiovascular risk reduction is β-blocker. They reduce heart rate, myocardial contractility, and hence decrease myocardial oxygen consumption. Studies are very heterogeneous, but there is evidence for a decrease in perioperative cardiac mortality and MIs in patients with clinical risk factors undergoing high-risk surgery<sup>
<xref ref-type="bibr" rid="bibr1-0003319712440874">1</xref>,<xref ref-type="bibr" rid="bibr2-0003319712440874">2</xref> </sup>(class I recommendation, level B evidence). Intermediate-risk patients are also likely to benefit, but this is still the subject of debate. Conversely though, there is evidence that they might be harmful in low-risk patients (especially if only started on the day of the operation), mainly by increasing the stroke risk due to bradycardia and hypotension.<sup>
<xref ref-type="bibr" rid="bibr12-0003319712440874">12</xref>
</sup> β-Blockers with a long half-life and without intrinsic sympathomimetic activity, such as bisoprolol, are preferred. The latter should ideally be started between 30 days and at least 1 week before surgery and titrated carefully up to achieve a heart rate between 60 and 80 beats/min, maintaining a systolic blood pressure of &gt;100 mm Hg. Once started, interruption of β-blocker therapy should be avoided in the perioperative period.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712440874">1</xref>
</sup>
</p>
<p>The beneficial effects of perioperative statin use have been show in several large clinical trials, with mortality reductions of over 50% reported.<sup>
<xref ref-type="bibr" rid="bibr13-0003319712440874">13</xref>
</sup> They exert pleiotropic or nonlipid effects and are thought to stabilize coronary plaque preventing plaque rupture and MI during the surgical stress. Similar to β-blocker, it is recommended that they are started in high-risk surgical patients, optimally between 30 days and at least 1 week before surgery. Atorvastatin, rosuvastatin, or fluvastatin are frequently used.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712440874">1</xref>
</sup>
</p>
<p>The evidence for the use of angiotensin-converting enzyme (ACE) inhibitors to improve outcome in the perioperative period is less robust. Studies have shown conflicting results, with the main concerns around hypotension. The guidelines recommend ACE inhibitors in patients with left ventricular systolic dysfunction scheduled for high-risk surgery and advise to consider them in low- or intermediate-risk interventions.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712440874">1</xref>
</sup>
</p>
<p>Surprisingly, the evidence for aspirin reducing perioperative events is limited. It is recommended that aspirin should be continued in patients previously treated with it and only withheld if the bleeding risks outweigh the potential cardiac benefit.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712440874">1</xref>
</sup> Patients on antiplatelet therapy after having undergone cardiac stenting procedures should be discussed individually with the treating cardiologist. One has to bear in mind the high mortality rates of stent thrombosis when antiplatelets are stopped prematurely, especially with drug-eluting stents.<sup>
<xref ref-type="bibr" rid="bibr1-0003319712440874">1</xref>
</sup>
</p>
</sec>
<sec id="section7-0003319712440874">
<title>Putting It All Into Practice</title>
<p>
<xref ref-type="fig" rid="fig1-0003319712440874">Figure 1</xref> shows a summary of the proposed stepwise approach to cardiac risk evaluation and perioperative management as recommended by the ESC. Initially it is important to assess, whether urgent surgery is needed. Should this be the case, no further testing is necessary and the patient can be taken to theater. Similarly, if the estimated risk of the procedure is low, it is unlikely that any test results will alter the management, and surgery can go ahead. If the patient has an unstable cardiac condition as outlined in <xref ref-type="table" rid="table3-0003319712440874">Table 3</xref>, they should be referred to a cardiologist urgently to undergo coronary angiography with a view to intervention, as for all patients with acute coronary syndromes, irrespective of surgery. For stable patients, the next step is the assessment of functional capacity. If the patient is able to exercise in equivalent of more than 4 METs, testing is deemed unnecessary and the patient can undergo surgery. Patients with poor or unknown functional capacity can be referred for intermediate-risk surgery, as long as they undergo optimization/adaptation of their medication regimen as outlined above. A similar approach seems reasonable in patients undergoing high-risk surgery and ≤2 risk factors. Only patients scheduled for high-risk surgery with ≥3 cardiovascular risk factors should be considered for noninvasive cardiac assessment. Should this show extensive ischemia, an individualized approach to perioperative management is recommended. The potential benefit of the proposed surgical procedure should be weighed against the periprocedural risk. Prophylactic revascularization may be considered (class IIb recommendation, level B evidence), according to the standard ESC guidelines on stable angina pectoris,<sup>
<xref ref-type="bibr" rid="bibr14-0003319712440874">14</xref>
</sup> although the evidence for a reduction in surgical risk is limited, and revascularization might be reserved for only the most severe lesions that carry a prognostic risk, irrespective of the surgery.</p>
<fig id="fig1-0003319712440874" position="float">
<label>Figure 1.</label>
<caption>
<p>Summary of the stepwise approach to preoperative risk evaluation.</p>
</caption>
<graphic xlink:href="10.1177_0003319712440874-fig1.tif"/>
</fig>
<table-wrap id="table3-0003319712440874" position="float">
<label>Table 3.</label>
<caption>
<p>Unstable Cardiac Conditions</p>
</caption>
<graphic alternate-form-of="table3-0003319712440874" xlink:href="10.1177_0003319712440874-table3.tif"/>
<table>
<tbody>
<tr>
<td>Unstable angina pectoris</td>
</tr>
<tr>
<td>Acute heart failure</td>
</tr>
<tr>
<td>Significant cardiac arrhythmias</td>
</tr>
<tr>
<td>Symptomatic valvular heart disease</td>
</tr>
<tr>
<td>Recent MI and residual myocardial ischemia</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0003319712440874">
<p>Abbreviation: MI, myocardial infraction.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>We have provided a brief overview of the current guidelines on preoperative cardiovascular risk management. The most effective strategy to reduce risk—at least in stable patients—lies in pharmacological plaque stabilization and myocardial protection, more than coronary revascularization. Noninvasive cardiac testing should be reserved for selected patients if it is likely to change perioperative management and often serves to advise on perioperative risk rather than guide revascularization. Further trials may help define a subset of patients that might benefit from revascularization and answer some of the outstanding questions in this field (<xref ref-type="table" rid="table4-0003319712440874">Table 4</xref>).</p>
<table-wrap id="table4-0003319712440874" position="float">
<label>Table 4.</label>
<caption>
<p>Important Studies in the Field of Preoperative/Perioperative Management</p>
</caption>
<graphic alternate-form-of="table4-0003319712440874" xlink:href="10.1177_0003319712440874-table4.tif"/>
<table>
<thead>
<tr>
<th>Study</th>
<th>Number of Patients</th>
<th>Patients Characteristics</th>
<th>Methods</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARP <sup>
<xref ref-type="bibr" rid="bibr9-0003319712440874">9</xref>
</sup>
</td>
<td>510</td>
<td>1- to 2-vessel disease; normal LV function</td>
<td>Revascularization vs medical therapy before major vascular surgery</td>
<td>No significant difference in perioperative incidence of MI, death, or length of stay. No significant difference in mortality at 2.7 years</td>
</tr>
<tr>
<td>DECREASE V<sup>10</sup>
</td>
<td>101</td>
<td>3 or more risk factors. Extensive stress-induced ischemia during noninvasive testing</td>
<td>Revascularization vs medical therapy before vascular surgery</td>
<td>No significant difference in mortality at 2.8 years</td>
</tr>
<tr>
<td>DECREASE I<sup>
<xref ref-type="bibr" rid="bibr2-0003319712440874">2</xref>
</sup>
</td>
<td>112</td>
<td>High-risk vascular surgery patients</td>
<td>Bisoprolol (started at least 1 week before surgery) or placebo</td>
<td>Reduction in perioperative nonfatal MI and death from 34% to 3.4%</td>
</tr>
<tr>
<td>Lindenauer et al<sup>
<xref ref-type="bibr" rid="bibr15-0003319712440874">15</xref>
</sup>
</td>
<td>663.635</td>
<td>300 US hospitals; with wide variety of surgical procedures</td>
<td>Retrospective cohort study. β-blocker perioperatively</td>
<td>Possible harm for low risk patients: RCRI score 2: OR, 0.88; NNT, 227; RCRI score 3: OR, 0.71; NNT, 62; RCRI score ≥4: OR, 0.58; NNT 33</td>
</tr>
<tr>
<td>DECREASE II<sup>
<xref ref-type="bibr" rid="bibr16-0003319712440874">16</xref>
</sup>
</td>
<td>770</td>
<td>Intermediate risk vascular surgery patients. Already on β-blocker</td>
<td>Preoperative cardiac stress testing vs no stress testing</td>
<td>No difference in cardiac death and MI at 30 days</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0003319712440874">
<p>Abbreviations: RCRI, revised cardiac risk index; OR, adjusted odds ratio for death in hospital; NNT, numbers needed to treat; CARP, Coronary Artery Revascularisation Prophylaxis; DECREASE, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography; LV, left ventricle.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319712440874">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319712440874">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319712440874">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poldermans</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bax</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Boersma</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery</article-title>. <source>Eur Heart J</source>. <year>2009</year>;<volume>30</volume>(<issue>22</issue>):<fpage>2769</fpage>–<lpage>2812</lpage>.</citation>
</ref>
<ref id="bibr2-0003319712440874">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poldermans</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Boersma</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bax</surname>
<given-names>JJ</given-names>
</name>
<etal/>
</person-group>. <article-title>The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group</article-title>. <source>N Engl J Med</source>. <year>1999</year>;<volume>341</volume>(<issue>24</issue>):<fpage>1789</fpage>–<lpage>1794</lpage>.</citation>
</ref>
<ref id="bibr3-0003319712440874">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Marcantonio</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Mangione</surname>
<given-names>CM</given-names>
</name>
<etal/>
</person-group>. <article-title>Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery</article-title>. <source>Circulation</source>. <year>1999</year>;<volume>100</volume>(<issue>10</issue>):<fpage>1043</fpage>–<lpage>1049</lpage>.</citation>
</ref>
<ref id="bibr4-0003319712440874">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Detsky</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Abrams</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Forbath</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Hilliard</surname>
<given-names>JR</given-names>
</name>
</person-group>. <article-title>Cardiac assessment for patients undergoing noncardiac surgery. A multifactorial clinical risk index</article-title>. <source>Arch Intern Med</source> <year>1986</year>;<volume>146</volume>:<fpage>2131</fpage>–<lpage>2134</lpage>.</citation>
</ref>
<ref id="bibr5-0003319712440874">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldman</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Caldera</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Nussbaum</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Southwick</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Krogstad</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>O’Malley</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Goroll</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Caplan</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Nolan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Carabello</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Slater</surname>
<given-names>EE</given-names>
</name>
</person-group>. <article-title>Multifactorial index of cardiac risk in noncardiac surgical procedures</article-title>. <source>N Engl J Med</source> <year>1977</year>;<volume>297</volume>:<fpage>845</fpage>–<lpage>850</lpage></citation>
</ref>
<ref id="bibr6-0003319712440874">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devereaux</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial</article-title>. <source>Lancet</source>. <year>2008</year>;<volume>371</volume>(<issue>9627</issue>):<fpage>1839</fpage>–<lpage>1847</lpage>.</citation>
</ref>
<ref id="bibr7-0003319712440874">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boersma</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kertai</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Schouten</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>Perioperative cardiovascular mortality in noncardiac surgery: validation of the Lee cardiac risk index</article-title>. <source>Am J Med</source>. <year>2005</year>;<volume>118</volume>(<issue>10</issue>):<fpage>1134</fpage>–<lpage>1141</lpage>.</citation>
</ref>
<ref id="bibr8-0003319712440874">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morris</surname>
<given-names>CK</given-names>
</name>
<name>
<surname>Ueshima</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kawaguchi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hideg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Froelicher</surname>
<given-names>VF</given-names>
</name>
</person-group>. <article-title>The prognostic value of exercise capacity: a review of the literature</article-title>. <source>Am Heart J</source>. <year>1991</year>;<volume>122</volume>(<issue>5</issue>):<fpage>1423</fpage>–<lpage>1431</lpage>.</citation>
</ref>
<ref id="bibr9-0003319712440874">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McFalls</surname>
<given-names>EO</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Moritz</surname>
<given-names>TE</given-names>
</name>
<etal/>
</person-group>. <article-title>Coronary-artery revascularization before elective major vascular surgery</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>351</volume>(<issue>27</issue>):<fpage>2795</fpage>–<lpage>2804</lpage>.</citation>
</ref>
<ref id="bibr10-0003319712440874">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schouten</surname>
<given-names>O</given-names>
</name>
<name>
<surname>van Kuijk</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Flu</surname>
<given-names>WJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-term outcome of prophylactic coronary revascularization in cardiac high-risk patients undergoing major vascular surgery (from the randomized DECREASE-V Pilot Study)</article-title>. <source>Am J Cardiol</source>. <year>2009</year>;<volume>103</volume>(<issue>7</issue>):<fpage>897</fpage>–<lpage>901</lpage>.</citation>
</ref>
<ref id="bibr11-0003319712440874">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fleisher</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Bax</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>KA</given-names>
</name>
<etal/>
</person-group>. <article-title>ACC/AHA 2007 Guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary</article-title>. <source>Circulation</source>. <year>2007</year>;<volume>116</volume>(<issue>17</issue>):<fpage>1971</fpage>–<lpage>1996</lpage>.</citation>
</ref>
<ref id="bibr12-0003319712440874">
<label>12</label>
<citation citation-type="journal">
<collab collab-type="author">POISE Study Group</collab>, <person-group person-group-type="author">
<name>
<surname>Devereaux</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial</article-title>. <source>Lancet</source>. <year>2008</year>;<volume>371</volume>(<issue>9627</issue>):<fpage>1839</fpage>–<lpage>1847</lpage>.</citation>
</ref>
<ref id="bibr13-0003319712440874">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hindler</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Samuels</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fulton</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Collard</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Riedel</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Improved postoperative outcomes associated with preoperative statin therapy</article-title>. <source>Anaesthesiology</source>. <year>2006</year>;<volume>105</volume>(<issue>6</issue>):<fpage>1260</fpage>–<lpage>1272</lpage>.</citation>
</ref>
<ref id="bibr14-0003319712440874">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fox</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Ardissino</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Guidelines on the management of stable angina pectoris</article-title>. <source>Eur Heart J</source>. <year>2006</year>;<volume>27</volume>(<issue>11</issue>):<fpage>1341</fpage>–<lpage>1381</lpage>.</citation>
</ref>
<ref id="bibr15-0003319712440874">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindenauer</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Pekow</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mamidi</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Gutierrez</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Benjamin</surname>
<given-names>EM</given-names>
</name>
</person-group>. <article-title>Perioperative beta-blocker therapy and mortality after major noncardiac surgery</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>353</volume>(<issue>4</issue>):<fpage>349</fpage>–<lpage>361</lpage>.</citation>
</ref>
<ref id="bibr16-0003319712440874">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poldermans</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bax</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Schouten</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group>. <article-title>Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight heart rate control?</article-title> <source>J Am Coll Cardiol</source>. <year>2006</year>;<volume>48</volume>(<issue>5</issue>):<fpage>964</fpage>–<lpage>969</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>